Topical N-phosphonacetyl-l-aspartate is a dual action candidate for treating non-melanoma skin cancer.

ABSTRACT: Each year, 3.3 million Americans are diagnosed with non-melanoma skin cancers (NMSC) and an additional 40 million individuals undergo treatment of precancerous actinic keratosis lesions. The most effective treatments of NMSC (surgical excision and Mohs surgery) are invasive, expensive and require specialised training. More readily accessible topical therapies currently are 5-fluorouracil (a chemotherapeutic agent) and imiquimod (an immune modulator), but these can have significant side effects which limit their efficacy. Therefore, more effective and accessible treatments are needed for non-melanoma cancers and precancers. Our previous work demonstrated that the small molecule N-phosphonacetyl-L-aspartate (PALA) both inhibits pyrimidine nucleotide synthesis and activates pattern recognitio

SUBMITTER: Mahen KK 

PROVIDER: S-EPMC10527533 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature